---
title: "U.S. Stock Movement | Avidity Biosciences soars over 42% after being acquired by NOVARTIS AG for $12 billion"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262919825.md"
description: "On Monday, Avidity Biosciences opened with a surge of over 42%, reaching a historic high of $70.13. In terms of news, Swiss pharmaceutical company NOVARTIS AG has agreed to acquire the American biotechnology company Avidity Biosciences, with the acquisition deal valued at $12 billion. NOVARTIS AG stated that it will acquire shares at a cash price of $72 per share, which represents a 46% premium over Avidity's closing price on Friday. The company also mentioned that the equity value of the transaction is $12 billion, but after the deal is completed, Avidity is expected to have approximately $1 billion in cash, bringing its enterprise value to about $11 billion. This makes it NOVARTIS AG's largest acquisition in nearly a decade. The entire transaction is expected to be completed in the first half of 2026, but is contingent upon the completion of the spin-off matters"
datetime: "2025-10-27T13:47:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262919825.md)
  - [en](https://longbridge.com/en/news/262919825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262919825.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/262919825.md) | [English](https://longbridge.com/en/news/262919825.md)


# U.S. Stock Movement | Avidity Biosciences soars over 42% after being acquired by NOVARTIS AG for $12 billion

According to Zhitong Finance APP, on Monday, Avidity Biosciences (RNA.US) opened with a surge of over 42%, reaching a historic high of $70.13. In terms of news, Swiss pharmaceutical company Novartis AG (NVS.US) has agreed to acquire the American biotechnology company Avidity Biosciences, with the acquisition valued at $12 billion. Novartis stated that it will purchase shares at a cash price of $72 each, which represents a 46% premium over Avidity's closing price on Friday.

Novartis also mentioned that the equity value of the transaction is $12 billion, but after the deal is completed, Avidity is expected to have approximately $1 billion in cash, bringing its enterprise value to about $11 billion. This makes it Novartis's largest acquisition in nearly a decade. The entire transaction is expected to be completed in the first half of 2026, but is contingent upon the completion of the spin-off matters

### 相關股票

- [NOVARTIS AG (NVS.US)](https://longbridge.com/zh-HK/quote/NVS.US.md)
- [Atrium Therapeutics (RNA.US)](https://longbridge.com/zh-HK/quote/RNA.US.md)

## 相關資訊與研究

- [This stock popped 15% in its trading debut. Meet Quantum’s new kid on the block.](https://longbridge.com/zh-HK/news/281082698.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/zh-HK/news/281323250.md)
- [Norfolk Southern Earnings Preview: What to Expect](https://longbridge.com/zh-HK/news/280999046.md)
- [Port Houston March 2026 Meeting: Project 11 Expansion Recognized for Engineering Excellence](https://longbridge.com/zh-HK/news/281435223.md)
- [Iterum Therapeutics Files Wind Up Petition; Shares Shoot In Pre-market](https://longbridge.com/zh-HK/news/280999380.md)